The following represents disclosure information provided by authors of this abstract. The Genitourinary Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Enzalutamide after abiraterone in patients with metastatic castrate-resistant prostate cancer (mCRPC).
Gurprataap Singh Sandhu
No relevant relationships to disclose
Rahul Atul Parikh
No relevant relationships to disclose
Leonard Joseph Appleman
No relevant relationships to disclose
David Friedland
No relevant relationships to disclose